

Financial Statements
for the 3rd quarter of fiscal year ending March 31, 2013
(From Apr. 1, 2012 to Dec. 31, 2012)

Summary of consolidated results

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.

Highlights in Business Results



Increased both in Sales and Profit for the 3rd Quarter of FYE Mar. 2013

(%: compared with previous year)

Sales: JPY 36.7 billion, up 5.9%

Sales

[Japan]

-Continued growth in the sales of Infusion and Transfusion-related products and hemodialysis blood tubing sets

[Overseas]

-Positive sales of apheresis kits for OEM business and safety scalp vein sets
-Continued solid sales of AV fistula needles for China

Operating income: JPY 1.6 billion (up 79.3%), Ordinary income: JPY 1.9 billion (up 58.3%),
Net income: JPY 1.3 billion (up 74.8%)

Profit

-Increase of revenues offsetting fixed expenses such as labor costs
-Inclusion of equity in earnings of affiliates

Revision of consolidated business forecast for the FYE Mar. 2013

-Due to the exchange rate movement and the increase of manufacturing costs in emerging countries.

Consolidated Business Results



Increased both in Sales and Profit

(unit: JPY million)


	Results Apr. - Dec. 2011	Results Apr. - Dec. 2012	Year – over – Year
Sales	34,701	36,733	5.9%
Operating Income	919	1,649	79.3%
Ordinary Income	1,224	1,937	58.3%
Net Income	797	1,394	74.8%
Net Income per share	JPY 18.48	JPY 32.31	---

Sales by segment (geographical area)



Apr. – Dec. 2011 Apr. – Dec. 2012

(unit: JPY million)




Profit by segment (geographical area)



(unit: JPY million)

Apr. – Dec. 2011


Apr. – Dec. 2012



Summary by segment (geographical area)




%: year-over-year



Japan

Sales	30,268 JPY mil.	4.9%
Ordinary Income	1,328 JPY mil.	161.4%


-Continued growth in the sales of Infusion and Transfusion-related products and hemodialysis blood tubing sets



Southeast Asia

Sales	10,517 JPY mil.	18.5%
Ordinary Income	267 JPY mil.	133.5%


-Positive sales of apheresis kits for the OEM customer and hemodialysis blood tubing sets for Japan



China

Sales	2,380 JPY mil.	9.8%
Ordinary Income	56 JPY mil.	(59.9%)

-Continued solid sales of AV fistula needles for the domestic market



Infusion set with a needleless access port, "PLANECTA"

Infusion set is used for drug administration to a human body. "PLANECTA" is a needleless access port, allowing connections without a needle, which offers minimized infection risk to patients and medical staff by reducing the risk of contamination coming from blood or solution, and preventing needle-stick accidents.



Hemodialysis blood tubing set

Hemodialysis tubing set is used for circulating blood by hemodialysis machine during dialysis therapy.

Summary by segment (geographical area)



?: year-over-year



Germany

Sales	1,869 JPY mil.	(13.9%)
Ordinary Income	97 JPY mil.	(46.1%)

Stagnant sales of AV Fistula needles and dialysis therapy chairs for EU market



United States

Sales	1,627 JPY mil.	1.2%
Ordinary Income	95 JPY mil.	(47.6%)

Despite the stagnant sales of AV Fistula needles for North America, the sales of safety scalp vein sets increased

AV Fistula Needle

AV fistula needle is for pulling blood from a patient during a dialysis therapy.



Others

Sales	884 JPY mil.	7.2%
Ordinary Income	108 JPY mil.	42.4%



Safety Scalp Vein set

Safety scalp vein set is an injection needle with tube for infusion and blood sampling. It has a safety function to prevent medical staff from accidental needle sticks.


Sales by Business Segment



(unit: JPY million)


Apr. – Dec. 2011

Apr. – Dec. 2012



Selling, General and Admin. Expenses


(unit: JPY million)



(unit: JPY million)

	Apr. - Dec. 2011	Apr. - Dec. 2012	Diff.	Year-over-Year
Labor Cost	3,772	3,918	146	3.9%
Transport	981	1,052	71	7.3%
R & D	1,043	945	(98)	(9.4%)
Depreciation	331	257	(74)	(22.4%)
Others	2,547	2,679	131	5.2%
Total	8,676	8,852	176	2.0%

Ordinary Income: Compared with the previous year



The underlined figures exclude impact of exchange rate.

Forecast for FYE Mar. 2013



(unit: JPY million)

	FYE Mar. 2012 Result	FYE Mar. 2013 Forecast		
		Previous Forecast	New Forecast	Amount Changed
Sales	46,836	48,000	48,000	---
Operating Income	1,052	2,300	2,000	(300)
Ordinary Income	1,382	2,500	2,200	(300)
Net Profit	942	1,550	1,400	(150)
Net profit per share	JPY 21.84	JPY 35.92	JPY 32.44	---

Consolidated business forecast for the fiscal year ending March 31, 2013 has been revised as shown above, due to the influence of exchange rate fluctuation on overseas affiliates' profit as well as the increase of manufacturing costs caused by political wage raise in emerging countries.

Topics



-Launching a new product “Safewing Cath”, a safety venous indwelling catheter for preventing the medical staff from the accidental needle sticks.

September 27, 2012

Safety venous indwelling catheter
[Safewing Cath]



-Announcement for the construction of electron beam sterilization facility

June 25, 2012



-Rendering-
E-Beam Sterilization Facility
In Chiyoda Plant (Hiroshima)

-Launching a new product “PEG ASSISTA”, an infusion system for semisolid nutrient

April 20, 2012

PEG ASSISTA
infusion system for semisolid nutrient



- Date shows the press release date.



The Bridge to Good Health Care



JMS will continue its activities for contributing to medical care, with our corporate philosophy “Patient comes first”.

JMS continue to dedicate effort to creating happiness for patients, their families and medical staff in line with its basic principle, **“Offering products and services creating an impression on customers”**.

Thank you very much for your patronage and support.